CRISPR New Evaluation Method for CRISPR Base Editors Captures Novel Off-Target Effects The method evaluates the editing specificity of cytosine base editors by detecting CBE-induced off-target sites across the genome. ERS Genomics Licenses CRISPR IP to GenOway ERS Genomics was founded to provide access to CRISPR-Cas9 intellectual property shared by Emmanuelle Charpentier, Jennifer Doudna, and others. Global Subway Metagenomics Study Reveals Cities' Microbial Fingerprints The study found more than 10,000 viruses and hundreds of bacteria not present in any reference database, along with other novel genomic features. Bioinformatics Method Could Improve Detection of Off-Target CRISPR Activity Premium Israeli researchers have developed CRISPector, which separates signal from noise better than earlier quality-control tools, a new paper shows. Dutch Seed Firm Bejo Takes License to Corteva Agriscience, Broad Institute CRISPR IP Corteva and Broad have been nonexclusively licensing their respective CRISRP-Cas9 intellectual property for agricultural applications since 2017. May 12, 2021 ERS Genomics Licenses CRISPR Patents to GenScript Biotech May 11, 2021 Sherlock Biosciences Foundation Grants License to Rokline Health for COVID-19 CRISPR Tests May 10, 2021 New CRISPR Base Editor Significantly Reduces DNA, RNA Off-Target Mutations May 3, 2021 Sherlock Bio Foundation Licenses CRISPR Tech to LogicInk Apr 29, 2021 New CRISPR Guide RNA Screen Helps Define Genetics of Spinal Cord Regeneration in Zebrafish Apr 28, 2021 CRISPRoff Reversible Epigenome Editing Method Could Enable Safer, More Precise Therapeutics Premium Apr 28, 2021 Twist Bioscience, Vivlion Partner on Guide RNA Libraries for CRISPR Applications Apr 26, 2021 TGen, Jumpcode Genomics Marrying NGS, CRISPR to Build a Better COVID-19 Test Premium Apr 21, 2021 Sherlock Bio Foundation Licenses CRISPR Tech to Cooper International, United PPE for COVID-19 Tests Apr 19, 2021 ERS Genomics Licenses CRISPR Patents to Nuvisan Apr 13, 2021 CRISPR-Cas9 Genome Editing Can Lead to Extensive Chromosome Rearrangements Apr 5, 2021 Using CRISPR-Chip Technology, Cardea Bio Aims to Develop Lab-Free Multi-Omic Technology Premium Apr 5, 2021 Inscripta Closes $150M Series E Financing Round Mar 30, 2021 Novel CRISPR-Cas12a Orthologs Expand Gene Editing Toolkit for Plants Premium Mar 24, 2021 DARPA Programs Leveraging Host-Response Testing, CRISPR for Future Pandemic Preparedness Premium Mar 17, 2021 Giraffe Genome Assembly, Functional Analyses Highlight Variants Linked to Height Adaptations Mar 10, 2021 ERS Genomics Licenses CRISPR Patents to Setsuro Tech Mar 8, 2021 CRISPR Screens Identify Host Factors Required for SARS-CoV-2 Infection Mar 3, 2021 ERS Genomics Licenses CRISPR Patents to Otsuka Pharmaceutical Feb 23, 2021 ERS Genomics Licenses CRISPR Patents to Korean Biotech Firm G+FLAS Life Sciences Load More Breaking News Enzo Biochem, CLX Health Partner to Support COVID-19 Testing for International Travel Type 1 Diabetes GWAS, Fine-Mapping Leads to New Genetic Loci, Potential Drug Targets LSU Health Sciences Center Wins $2.4M to Lead SARS-CoV-2 Variant Sequencing Program NanoString Technologies, Parker Institute for Cancer Immunotherapy Partner on Cell Therapy Project BGI Americas Collaborating With Champions Oncology on Proteomic Cancer Research Personal Genome Diagnostics Inks Cancer Genomic Profiling Deal with Duke University Health System The Scan Missed Early Cases A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports. Limited Journal Editor Diversity A survey finds low diversity among scientific and medical journal editors, according to The Scientist. How Much of a Threat? Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned. PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.